Biotech companies in the United States by one-year price change
How far the share price has moved over the last 52 weeks.
Moderna leads the 20 biotech companies in the United States ranked by one-year price change, at +780%, ahead of Kodiak Sciences (+399%) and Twist Bioscience (+346%). Figures as of 20 Nov 2026, 08:49 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 20
- First
- Moderna+780%
- Median
- +51.9%
- Combined market value
- TRY 37.17T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | 1 year ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | ModernaMRNA · Health Care | +780% | TRY 4.08T | TRY 10,081.05 | 1.29% up | 780% up | ||
| 2 | Kodiak SciencesKOD · Health Care | +399% | TRY 323.8B | TRY 4,951.26 | 0.09% up | 399% up | ||
| 3 | Twist BioscienceTWST · Health Care | +346% | TRY 384.9B | TRY 5,645.15 | 4.07% down | 346% up | ||
| 4 | ImmunityBioIBRX · Health Care | +232% | TRY 353.5B | TRY 332.28 | 1.94% down | 232% up | ||
| 5 | Revolution MedicinesRVMD · Health Care | +129% | TRY 1.74T | TRY 8,063.12 | 0.24% down | 129% up | ||
| 6 | CG OncologyCGON · Health Care | +96.5% | TRY 370B | TRY 4,142.07 | 2.38% up | 97% up | ||
| 7 | Kymera TherapeuticsKYMR · Health Care | +87.4% | TRY 515.5B | TRY 6,038.11 | 1.44% down | 87% up | ||
| 8 | Adaptive BiotechnologiesADPT · Health Care | +74.4% | TRY 229.6B | TRY 1,418.62 | 1.44% down | 74% up | ||
| 9 | ExelixisEXEL · Health Care | +63.5% | TRY 812.4B | TRY 3,329.33 | 3.60% down | 63% up | ||
| 10 | Krystal BiotechKRYS · Health Care | +54.4% | TRY 473.3B | TRY 15,972.50 | 0.15% up | 54% up | ||
| 11 | BiogenBIIB · Health Care | +49.5% | TRY 1.85T | TRY 12,498.53 | 1.70% down | 49% up | ||
| 12 | ImmunovantIMVT · Health Care | +45.5% | TRY 340.4B | TRY 1,644.69 | 1.96% down | 46% up | ||
| 13 | Halozyme TherapeuticsHALO · Health Care | +38.9% | TRY 536.5B | TRY 4,705.47 | 2.88% down | 39% up | ||
| 14 | Gilead SciencesGILD · Health Care | +35.2% | TRY 10.45T | TRY 8,422.20 | 1.45% down | 35% up | ||
| 15 | AmgenAMGN · Health Care | +32.1% | TRY 12T | TRY 22,193.19 | 1.14% down | 32% up | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | +26.2% | TRY 310.8B | TRY 2,547.45 | 4.94% up | 26% up | ||
| 17 | Bio-TechneTECH · Health Care | +23.9% | TRY 577.6B | TRY 3,676.78 | 0.07% down | 24% up | ||
| 18 | VaxcytePCVX · Health Care | +22.8% | TRY 467.2B | TRY 2,951.54 | 0.27% down | 23% up | ||
| 19 | Neurocrine BiosciencesNBIX · Health Care | +17.2% | TRY 801.6B | TRY 7,919.49 | 3.85% down | 17% up | ||
| 20 | RepligenRGEN · Health Care | +11.9% | TRY 550.5B | TRY 8,612.37 | 1.38% down | 12% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 50.5747 TRY).
Questions and answers
Which biotech companies in the United States rank first by one-year price change?
Moderna (+780%), Kodiak Sciences (+399%) and Twist Bioscience (+346%) are the top three of the 20 biotech companies in the United States ranked by one-year price change as of 20 Nov 2026, 08:49 UTC.
How many biotech companies in the United States are in this ranking?
20 are ranked by one-year price change.
What are these biotech companies in the United States worth together?
The 20 biotech companies in the United States ranked by one-year price change have a combined market value of TRY 37.17T as of 20 Nov 2026, 08:49 UTC.
What does ranking by one-year price change measure?
How far the share price has moved over the last 52 weeks.
Learn how this ranking works
All markets guides →- 52-week high and low: what the range tells you
A stock's 52-week high and low are the highest and lowest prices it reached over the past year. Where today's price sits in that range, from 0% at the low to 100% at the high, shows how the past year has gone. Sources differ on whether they use closing or intraday prices, so the same stock's range can differ slightly.
- Drawdown and recovery: why a 50% fall needs a 100% gain
A drawdown is how far a price has fallen from its previous peak, as a percentage of that peak. Recovery needs a larger gain than the fall, because the gain starts from a smaller base: a 20% drop needs a 25% rise to get back, a 50% drop needs 100%, and a 75% drop needs 300%.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech companies in the United States by one-year price change”, data as of 20 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=year-change
Underlying data: Yahoo Finance; SEC EDGAR.